肝细胞癌患者血浆BIRC5、ANXA-1抗体水平及在预后判断中的意义  

Levels of plasma BIRC5 and ANXA-1 antibodies in patients with hepatocellular carcinoma and their clinical prognostic significance

作　　者：齐锐 王何斌 李劲 杨茂辉 冯燕 徐杰 QI Rui;WANG Hebin;LI Jin;YANG Maohui;FENG Yan;XU Jie(Department of Hepatobiliary Surgery,Affiliated Hospital of Panzhihua College,Panzhihua,Sichuan 617000,China)

机构地区：[1]攀枝花学院附属医院肝胆科,四川攀枝花617000

出　　处：《国际检验医学杂志》2023年第3期306-310,共5页International Journal of Laboratory Medicine

基　　金：国家重大疑难病中西医临床协作试点项目(国中医药办医政发[2018]3号)。

摘　　要：目的探讨肝细胞癌患者血浆凋亡抑制因子(BIRC5)、膜联蛋白A1(ANXA-1)抗体水平及在预后判断中的意义。方法将2017年5月至2019年5月在该院进行治疗的121例肝细胞癌患者作为患者组。另外,选取同期健康体检者97例作为对照组。收集所有纳入研究者的血浆标本,采用酶联免疫吸附法检测各组血浆BIRC5、ANXA-1抗体水平。分析血浆BIRC5、ANXA-1抗体水平与肝细胞癌患者临床病理特征的关系,同时采用Kaplan-Meier生存曲线及多因素Cox回归分析法分析血浆BIRC5、ANXA-1抗体表达与肝细胞癌患者预后的关系。结果患者组血浆BIRC5a、ANXA-1抗体水平均明显高于对照组(P<0.05),两组血浆BIRC5b抗体水平比较差异无统计学意义(P>0.05)。肝细胞癌患者血浆中BIRC5a、ANXA-1抗体水平与临床分期、远处淋巴转移、门静脉侵犯有关(P<0.05),而肝细胞癌患者血浆BIRC5b抗体水平与年龄、性别、肿瘤最大径、临床分期、远处淋巴转移、门静脉侵犯均无明显关系(P>0.05)。采用受试者工作特征(ROC)曲线确定血浆BIRC5、ANXA-1抗体水平用于诊断肝细胞癌的截断值,并根据截断值分为BIRC5抗体高表达组(42例)、低表达组(79例)与ANXA-1抗体高表达组(43例)、低表达组(78例)。BIRC5、ANXA-1抗体高表达组3年生存率分别高于BIRC5、ANXA-1抗体低表达组(69.05%vs.29.11%、62.12%vs.30.77%,χ^(2)=17.844、14.734,P<0.05)。多因素Cox回归分析显示,BIRC5抗体>1.23(HR=0.35,95%CI:0.17~0.72)、ANXA-1抗体>1.01(HR=0.29,95%C`I:0.16~0.53)均可作为肝细胞癌患者预后的独立保护因素(P<0.05)。结论血浆BIRC5、ANXA-1抗体水平在肝细胞癌患者中均升高,而且这两种抗体高水平的患者3年生存率更高,可作为预测肝细胞癌患者预后的生物标志物。Objective To explore the plasma apoptosis inhibitory factor(BIRC5)and annexin A1(ANXA-1)antibody levels and their clinical prognostic significance in patients with hepatocellular carcinoma.Methods A total of 121 patients with hepatocellular carcinoma who were treated in the hospital from May 2017 to May 2019 were enrolled as the research group,and 97 healthy people during the same period were enrolled as the control group.Plasma specimens from the people enrolled in the study were collected,and the levels of BIRC5 and ANXA-1 antibodies in plasma of each group were detected by using enzyme-linked immunosorbent assay.The relationship between the expression of plasma BIRC5 and ANXA-1 antibodies and the clinicopathological characteristics of patients with hepatocellular carcinoma was analyzed.Kaplan-Meier survival curve and multivariate Cox regression analysis were used to analyze the relationship between plasma levels of BIRC5 and ANXA-1 antibodies and the prognosis of patients with hepatocellular carcinoma.Results The levels of plasma BIRC5a and ANXA-1 antibodies in the study group were significantly higher than those in the control group(P<0.05),but there was no significant difference in the levels of plasma BIRC5b antibodies between the two groups(P>0.05).The plasma levels of BIRC5a and ANXA-1 antibodies in patients with hepatocellular carcinoma were significantly correlated with clinical stage,distant node metastasis,and portal vein invasion(P<0.05).However,the plasma level of BIRC5b antibody in patients with hepatocellular carcinoma was not significantly related to age,gender,tumor size,clinical stage,distant lymph node metastasis and portal vein invasion(P>0.05).The cut-off value of plasma BIRC5 and ANXA-1 antibody expression levels in patients with hepatocellular carcinoma was determined by ROC curve,and according to the cut-off value,they were divided into BIRC5 antibody high expression group(42 cases),low expression group(79 cases)and ANXA-1 antibody high expression group(43 cases)and low expression group(7

关 键 词：肝细胞癌 凋亡抑制因子 膜联蛋白A1 自身抗体 预后 

分 类 号：R446.11[医药卫生—诊断学]